This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Compugen's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Stocks in this article: CGEN

Thirdly, in addition to our accomplishments in our areas of focus, we have in parallel identified opportunities to further develop and commercialize certain of our discoveries in diagnostic and/or therapeutic areas outside of these areas, whereby our shareholders would obtain the right to share in any future success from commercializing these discoveries but without the need to commit any further Compugen financial resources.

In recent months, we have announced a number of agreements including the announcement during the last quarter of the joint establishment with Merck Serono of a new biomarker company. And we expect to announce additional such arrangements in the future, thus significantly extending our strong base for future growth in shareholder value beyond our initial areas of focus.

As a discovery company, our underlying strategy is to maximize the returns to our shareholders from our multiple candidates through licensing and other arrangements with the industry and to do so at pre-selected key value enhancement point, relative of course to the cost of getting to these place [ph]. This business model offers exceptional potential shareholder value through the matching of our unique discovery capabilities with the enormous development capabilities existing in the biopharma industry but without any broadly applicable systematic source for attractive product candidates such as we have established.

The most recent decisions we have made in implementing the strategy and business model were; first, to provide further differentiation for our multiple product candidates, and second through license our monoclonal antibodies themselves rather than just the targets that we discover and validate. Anat in her remarks will provide additional information about our ongoing differentiation efforts. With respect to monoclonal antibodies, although the quality of the target is the most critical variable determining the value of any monoclonal antibody therapy, it is clear that under most circumstances we would achieve much greater value and leverage our discoveries more fully by licensing out the monoclonal antibody therapeutic candidates rather than the target.

3 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs